Metabolic & Cardiometabolic
GLP-1 receptor agonist decreases obesity
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 1.00
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
11 support 0 contradict 0 tested null 0 mixed · 11 sources, 11 independent groups
What the evidence shows
GLP-1 receptor agonists reduce body weight / adiposity in PCOS (BMI, weight, waist, WHR all significantly lowered).
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B 2025 · Scientific Reports | meta-analysis | supports | moderate | [FT-verified] Lin2025 meta GLP1RA in PCOS: reduced BMI/wt/WC; niche population; vault sources narrower than STEP/SURMOUNT |
| Rajamoorthi A et al 2026 · bioRxiv | animal | supports | moderate | Mouse model of maternal obesity; semaglutide administered preconception through lactation improved body composition and glucose metabolism in HFD-fed dams, persisting 10 weeks post-discontinuation. |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | high | ACP living systematic review and network meta-analysis of pharmacologic weight-management treatments. 'The review included 69 studies with a total of 112 511 participants. Thirty-seven studies were at low risk of bias.' Population is 'overweight or obesity (body mass index >=25 kg/m2) in adults' - NOT PCOS; the words PCOS and polycystic do not appear anywhere in the record. Finding on weight is unambiguous and directionally consistent with the claim: 'Nearly all studied interventions were more effective than placebo and/or LI in reducing weight. Semaglutide and tirzepatide showed the most favorable results across outcomes.' OFF-SCOPE for this PCOS-scoped claim on population, exactly as ev-s42229460 was handled for the sibling PCOS claim. Quality high as a review (69 RCTs, 37 low risk of bias, prospectively registered PROSPERO CRD42023491646, ACP-funded, no industry sponsor). Read from abstract only (2026-08-19). |
| Parlati AL et al 2026 · Clin Med Insights Cardiol. 2026;20:11795468261460202 | observational | supports | moderate | Narrative review, read from PMC full text (PMC13272863) 2026-08-19. Self-described scope: 'This narrative review is based on a selective overview of the major randomized clinical trials, cardiovascular outcome studies, and relevant mechanistic investigations on tirzepatide, with particular focus on the SURPASS, SURMOUNT, SURPASS-CVOT and SUMMIT programs.' No systematic search, no pooled estimate, no data of its own. On weight it restates SURMOUNT-1: 'In adults without diabetes in SURMOUNT-1, which had a 72-week treatment period, mean weight loss reached approximately 16%, 21.4%, and 22.5% with 5, 10, and 15 mg respectively, versus about 2.4% with placebo.' Direction is therefore not in doubt — but OFF-SCOPE on population for this PCOS-scoped claim: the strings PCOS, polycystic and ovar occur zero times in the full text, exactly as ev-s42296503 was handled here. Two further caveats recorded for the reader: the agent is tirzepatide, a DUAL GIP/GLP-1 receptor agonist, so its weight effect is not cleanly attributable to the claim's GLP-1 subject; and every trial it summarises is an Eli Lilly programme the vault already counts directly, so weighting it would double-count by construction. Authors declare no funding and no conflicts: 'The authors received no financial support for the research, authorship, and/or publication of this article.' |
| Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D 2022 · Fertil Steril 2022;118(2):371-381 | RCT | supports | moderate | Elkind-Hirsch 2022, Fertil Steril 118:371-381. Double-blind placebo-controlled phase-3 RCT, PCOS + obesity, n=82 randomized (liraglutide 3 mg 55 vs placebo 27), 32 wk, both arms on lifestyle: body weight -5.7% vs -1.4%, and 25 of 44 vs 5 of 23 achieved at least 5% loss. On-scope - the claim is itself scoped to PCOS. Read from ABSTRACT only; the prior [FT-verified] stamp is not reproducible and the source note's own provenance says abstract. Superseded on this claim by lin-2025, which pools it as Elkind-Hirsch 2022. |
| Zaman W, Amin A 2026 · Expert Opin Pharmacother. 2026 Jun;27(8):697-708 | observational | supports | low | Narrative expert-opinion review (Expert Opin Pharmacother 2026;27(8):697-708) of orforglipron, 'a once-daily oral glucagon-like peptide-1 receptor agonist'. Affirms the claim's direction only in prose - the review's stated content includes 'evidence supporting clinically meaningful weight reduction' - and hedges its own conclusion: 'its role should be interpreted cautiously: comparative efficacy may not exceed leading injectable incretin therapies, and long-term durability, persistence, affordability, and real-world safety remain uncertain.' No search strategy, no pooled estimate, no n, and no quantitative weight-loss figure of any kind; all underlying data are the Eli Lilly orforglipron trial programme, so this is not an independent vote alongside any primary orforglipron trial. Read at abstract grade 2026-08-19 (no full text retrievable within the permitted fetches); quality lowered to low accordingly. |
| Zhang Y et al 2026 · Diabetes Obes Metab | animal | supports | low | DIO-mouse test of three engineered GLP-1R-agonist Fc-fusion peptides, with mono-agonist GLP-1(A8G)-Fc as a control: all arms carry GLP-1R agonism and all lose weight, so the paper votes for the claim's direction only indirectly. Its measured comparison is between engineered dual molecules, not GLP-1R agonism vs vehicle - 'GLP-1(A8G)/GIP(1-30)-Fc produced the greatest body weight reduction (21.59%),' 'significantly outperforming GLP-1(A8G)/GIP(3-30)-Fc (14.5%; p < 0.001).' Abstract-only (no OA full text); n per arm, randomization and blinding not reported; one author affiliated with the sponsoring biotech despite a nil-COI declaration. Quality low. |
| Dubin RL et al 2026 · Obesity (Silver Spring) | observational | supports | moderate | Narrative update review (PubMed type: Review) of 40 DXA-based body-composition reports on GLP-1 RA-based agents by the same Pennington group that published the prior report. Sole reported result: 'In our updated review of 40 DXA-based reports, we found the mean (SD) % FFML was 29.1% (19.0%).' The comparator is a literature benchmark - 'The amount of weight that is lost as % fat-free mass (% FFML) with diet-induced weight loss is ~25% but is extremely variable.' - and the conclusion is that GLP-1 RA changes 'remain in the upper range of expected % FFML using other nonsurgical interventions for obesity.' No weight-change or fat-mass-change magnitude is reported, so the paper quantifies the COMPOSITION of weight loss, not whether weight/adiposity fell. |
| Castro-Gamboa J et al 2026 · Cureus | observational | supports | low | Narrative review (non-systematic; 245 records screened, 35 orforglipron-focused sources retained plus 7 comparator trials) positioning orforglipron, 'an oral, nonpeptide, small-molecule glucagon-like peptide-1 receptor agonist developed for type 2 diabetes and obesity', against 'injectable semaglutide as a high-efficacy class comparator'. Affirms the class direction but reports no weight endpoint or magnitude; the authors state 'indirect comparisons remain limited by differences in populations, doses, follow-up duration, comparators, and endpoints' and conclude orforglipron is 'not a broadly superior replacement for existing agents'. Review role, zero-weight; quality low for a Cureus narrative synthesis with no primary data. |
| Li Y et al 2026 · Pharmacological Research | meta-analysis | supports | moderate # adjudicated calibration #18 (2026-08-19): abstract-only basis — the "high confidence" label's reach is unverifiable without full text, RoB unread, n=1230, pediatric cohort on an adult-scoped claim; standard abstract-provenance temper | Bayesian network meta-analysis of 17 RCTs (n=1230) in CHILDREN AND ADOLESCENTS with overweight/obesity, with or without T2D. Semaglutide 2.4mg SC gave the largest reductions in body weight (MD -18.00 kg, 95% CrI -24.34 to -11.69, authors' confidence: high), BMI (-5.9 kg/m2, -10.5 to -1.3, high confidence) and waist circumference (-12.2 cm, -21.67 to -2.67). Direction is unambiguous across the whole interval. Authors' own caveat: 'These findings are hypothesis-generating: most active-treatment comparisons were indirect, many nodes were informed by single trials, and SUCRA rankings should not be interpreted as evidence of definitive clinical superiority' — that caveat governs which AGENT is best, not whether GLP-1RA beats placebo on weight. Also reported: 'No agent improved lipid profiles in a statistically significant manner.' Abstract-only (not open access); risk-of-bias and heterogeneity statistics unread. Population is pediatric, outside the claim's declared adult scope. |
| Hamarsheh S, Jaber AR, Abu-Khazneh O, Andonie CR, Majadleh S, Zahran A, Ayesh H 2026 · Endocrinol Diabetes Metab | meta-analysis | supports | moderate | Frequentist random-effects network meta-analysis, 25 RCTs / 34,259 participants / 12 interventions, adults with overweight or obesity and explicitly 'without DM' (no PCOS population); protocol prospectively registered on OSF (10.17605/OSF.IO/BFH6S); PRISMA-NMA, RoB 2 ('Overall, 19 of 25 trials were judged to be at low risk of bias'), CINeMA certainty. GLP-1RA MONOTHERAPY vs placebo on percent body weight: semaglutide 2.4 mg MD -11.41% (95% CI -12.74 to -10.08; p < 0.0001) and semaglutide 7.2 mg MD -14.66% (95% CI -18.48 to -10.84; p < 0.0001) - verbatim, 'the 7.2 mg dose demonstrated greater weight reduction... than the standard 2.4 mg dose'. Dual/combination agents rank above monotherapy (tirzepatide 15 mg -17.97%, CagriSema -17.84%/-17.46%), which is context, not this claim's subject. Supporting anthropometrics agree: semaglutide 2.4 mg waist -8.35 cm, BMI -4.37 kg/m2. Honest ceiling: heterogeneity is severe (I2 = 89.4% for percent weight) and the authors' own CINeMA rates continuous weight outcomes Low to Very Low certainty, reaching High only at the >=20% responder threshold (where semaglutide 2.4 mg vs placebo is rated High). Most included trials were industry-sponsored, which the authors declare. Full text + full Supporting Information read 2026-08-19. |
| Damhof MA, van Bruggen FH, van Roon EN 2026 · Diabetes Obes Metab | observational | supports | moderate | Review on weight regain after GLP-1RA discontinuation; explicitly states GLP-1RAs 'produce substantial and sustained weight loss during active treatment,' with regain occurring only after cessation. |
| Abid M et al 2026 · Diabetes Metab Syndr Obes. 2026;19:566414 (Dove Medical Press) | observational | supports | low | Narrative review, read from PMC full text (PMC13271900) 2026-08-19. No data of its own: 'No formal meta-analysis was conducted, and data were synthesized narratively to highlight trends in efficacy, safety, and mechanistic differences among single, dual, and triple incretin-based therapies', and 'Data sharing is not applicable to this article as no new data were created or analysed in this study.' On weight it restates STEP TEENS: 'A total of 201 adolescents aged 12–18 years were randomized to receive once-weekly semaglutide (2.4 mg) or placebo' and 'Adolescents treated with semaglutide achieved a mean BMI reduction of 16.1%, compared with a 0.6% reduction in the placebo group', with '73% of participants receiving semaglutide achieved at least a 5% reduction in body weight'; liraglutide is more modest — 'Participants receiving liraglutide achieved a mean BMI reduction of 4.3%, compared with a 0.3% reduction observed in the placebo group.' Direction is therefore not in doubt, but the appraisal is OFF-SCOPE on population for this PCOS-scoped claim: no PCOS cohort is enrolled, subgrouped or even mentioned. CORRECTION TO THE PRIOR EXTRACT, which read the effect as '~16% mean body weight reduction': that figure is the paper's ABSTRACT wording for what its own body reports as 'a mean BMI reduction of 16.1%', and Table 3 then relabels the same number '% Weight Reduction' — the review uses BMI-percent and body-weight-percent interchangeably (the same slippage hits liraglutide: 4.3% BMI in the trial section, 'a mean weight loss of 4.3% after 56 weeks' in Table 3, against a separately stated ~5 kg). Quality is therefore low, not moderate: no protocol, no PRISMA, no risk-of-bias appraisal, Google Scholar in the search stack, an adverse-event table sourced only as 'Percentages are approximate incidence rates from phase 2/3 clinical trials as cited in the main text', a stated 2010-2024 search window that does not match its 2026 citations, and copy-editing failures including 'glucagon-like peptie-1' in the abstract. Note also that every number here comes from trials the vault counts directly (STEP TEENS, the liraglutide adolescent RCT, SURMOUNT-1, retatrutide phase-2, mazdutide pooled), so weighting this source would double-count them. Authors declare 'No funding was received for this study.' and 'The authors declare no competing interests.' |
| Bruna-Mejias A et al 2026 · Nutrients | meta-analysis | supports | low | [FT+suppl re-read 2026-08-19] PROSPERO SR+MA (CRD420261360837; 48 reports / 35 parent trials) of GLP-1RA/incretin therapy added to a lifestyle background in adults with overweight or obesity - no PCOS population anywhere in the paper. Primary kg-scale pooling of 8 comparisons: 'MD -10.08 kg, 95% CI -12.76 to -7.39'; separate %-scale pooling of 11 comparisons: 'MD -9.53 percentage points, 95% CI -11.92 to -7.14'. Direction is unambiguous, so supports stands. Quality lowered to low: the authors' own verdict is 'The certainty of evidence was rated as low for both kilogram-scale and percentage-scale body-weight change' (I2 ~95%, RoB concerns), and Supplementary Table S4 contradicts the main text - it gives the kg model as I2=92.8%, tau2=7.55, Q(4)=40.56 with 'only five comparisons' and a prediction interval of -15.70 to 1.18 kg that crosses the null, and grades the %-scale outcome 'Very low' for serious imprecision, while section 3.7 claims no imprecision downgrade was needed because both intervals 'remained on the beneficial side of the null'. MDPI Nutrients, 17-day review; no external funding, no declared COI. |
| Babazadeh D et al 2026 · Obesity Pillars | observational | supports | low | Prospective SINGLE-ARM uncontrolled observational cohort (CRAVE, NCT06467604; analytic n=28 with attrition) of adults with obesity initiating semaglutide or tirzepatide for 24 weeks with no structured nutrition intervention: 'GLP-1 RA OMM therapy was associated with significant reductions in body weight, adiposity, and BIA-estimated skeletal muscle mass (all P < 0.001); with approximately one-quarter of weight loss attributable to estimated skeletal muscle mass.' Effect sizes are not reported in the available abstract and body composition is bioelectrical-impedance-estimated, not DXA. The authors state: 'Given the modest sample size and participant attrition, these findings should be considered exploratory and hypothesis-generating.' Senior clinical author reports advisory-board work for Novo Nordisk and Eli Lilly, the makers of both study drugs. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.